Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 19/20 | 0.49 |
| ▸ | F11 | P03951 | 10/20 | 0.49 |
| ▸ | TPSB2 | P20231 | 9/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17764399 | 0.91 | CFD (0.51) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL17764398 | 0.91 | CFD (0.51) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL16396343 | 0.86 | CFD (0.61) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL16402248 | 0.85 | CFD (0.67) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL17764455 | 0.85 | CFD (0.67) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL16396368 | 0.84 | CFD (0.61) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL16410462 | 0.83 | CFD (0.52) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL16396648 | 0.82 | CFD (0.50) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL16410554 | 0.81 | CFD (0.51) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL17764293 | 0.81 | CFD (0.51) | CFDF11TPSB2KLKB1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | CFD 1/4885F11 17/4885TPSB2 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.